公开(公告)号：US20230183197A1

公开(公告)日：2023-06-15

申请号：US17925493

申请日：2020-06-01

申请人： NeoPhore Limited

发明人： Julian Blagg ,  Jon Roffey ,  Martin Drysdale ,  Paul Winship ,  David Clark

IPC分类号： C07D295/16 ,  C07D239/26 ,  C07D209/44 ,  C07D207/12 ,  C07D211/42 ,  C07D213/16 ,  C07D471/04 ,  C07D231/12 ,  C07D249/04 ,  C07D401/12 ,  C07D217/04 ,  C07D217/16 ,  C07D265/36 ,  C07D209/08 ,  C07D215/08 ,  C07D405/12 ,  C07D401/04 ,  C07D403/12 ,  C07D403/04 ,  A61K45/06

CPC分类号： C07D295/16 ,  C07D239/26 ,  C07D209/44 ,  C07D207/12 ,  C07D211/42 ,  C07D213/16 ,  C07D471/04 ,  C07D231/12 ,  C07D249/04 ,  C07D401/12 ,  C07D217/04 ,  C07D217/16 ,  C07D265/36 ,  C07D209/08 ,  C07D215/08 ,  C07D405/12 ,  C07D401/04 ,  C07D403/12 ,  C07D403/04 ,  A61K45/06

摘要： The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process:




wherein R1, R2, R3, R4, R6 and R10 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which MLH1 and/or PMS2 activity is implicated.